Aclaris Therapeutics, Inc. – Employment Agreement (May 9th, 2017)
This EMPLOYMENT AGREEMENT (the "Employment Agreement"), effective as of, and contingent upon, the effectiveness of the registration statement for Employer's initial public offering ("Agreement Effective Date"), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware ("Employer") and Kamil Ali-Jackson ("Executive").
Aclaris Therapeutics, Inc. – Fourth Amendment to Amended and Restated Sublease (March 15th, 2017)
This Fourth Amendment to the Amended and Restated Sublease ("Fourth Amendment") made and entered into this 24th day of October 2016 and effective as of October 1, 2016 ("Effective Date"), by and between NST CONSULTING, LLC, hereinafter referred to as "Sublandlord" and ACLARIS THERAPEUTICS, INC, hereinafter referred to as "Subtenant".
Aclaris Therapeutics, Inc. – Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 in Treating Seborrheic Keratosis, a Common Undertreated Skin Condition Pivotal Data Show Topical Treatment Delivered Statistically Significant Results, Meeting All Primary and Secondary Endpoints Aclaris to Submit New Drug Application to FDA in 1Q17 Company to Host Conference Call Today at 5:00 PM ET (November 15th, 2016)
Malvern, Pa., Nov. 15, 2016 - Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led clinical-stage pharmaceutical company focused on defining new standards of care in medical and aesthetic dermatology, today announced that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution (A-101), a novel treatment for seborrheic keratosis (SK) met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of SK lesions.
Aclaris Therapeutics, Inc. – Amendment to Assignment Agreement (June 17th, 2016)
This Amendment to Assignment Agreement (the "Amendment") is entered into effective as of June 15, 2016, by and between ACLARIS THERAPEUTICS, INC., a Delaware corporation, having an address of 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 ("Assignee"), and MICKEY J. MILLER, II, of 5757 Preston View Blvd, Appt. #130, Dallas, Texas 75240, as Personal Representative of the estate of Mickey J. Miller ("Miller Estate").
Aclaris Therapeutics, Inc. – Securities Purchase Agreement (June 2nd, 2016)
This SECURITIES PURCHASE AGREEMENT (this "Agreement") is made and entered into as of May 27, 2016 by and among Aclaris Therapeutics, Inc., a Delaware corporation (the "Company"), and the Investors identified on Exhibit A attached hereto (each an "Investor" and collectively the "Investors").
Aclaris Therapeutics, Inc. – Registration Rights Agreement (June 2nd, 2016)
This Registration Rights Agreement (this "Agreement") is made and entered into as of May 27, 2016 by and among Aclaris Therapeutics, Inc., a Delaware corporation (the "Company"), and the "Investors" named in that certain Securities Purchase Agreement by and among the Company and the Investors (the "Purchase Agreement"). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.